A significant interaction exists between the effects of rosuvastatin and the plasma concentration of B-type natriuretic peptide, or NT-proBNP, resp. Rosuvastatin decreases rate of major cardiovascular events (CV-death + myocardial infarction + stroke) only in the patients with chronic heart failure and low NT-proBNP plasma concentration.